Sep 23, 2026 | 2026, Investors, Press Releases
more detailsSep 23, 2026 | 2026, Investors, Press Releases
more detailsAug 17, 2026 | Press Releases
Longer-term analysis confirms the clinical benefit of neoadjuvant Nidlegy™ in locally advanced, fully resectable melanoma The publication represents an update of the PIVOTAL Phase III results previously published in Annals of Oncology, with longer follow-up and...Jul 27, 2026 | Press Releases
Siena, Italy, 27 July 2026 – Philogen S.p.A. (BIT:PHIL) is pleased to announce the submission of an updated Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the approval of Nidlegy™, an investigational product for the...May 21, 2026 | 2026, Investors, Press Releases
More detailsMay 12, 2026 | 2026, Investors, Press Releases
more details
Recent Comments